Fulltime Holdings

Fulltime Healthcare is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the discovery and development of innovative biologics for oncology and autoimmune diseases. The company leverages its proprietary bifunctional antibody platform to create next-generation immunotherapies designed to overcome resistance to current treatments by modulating the tumor microenvironment. Its lead candidate, FT-001, is a PD-L1/TGF-beta bifunctional fusion protein currently undergoing clinical evaluation for various advanced solid tumors. Fulltime Healthcare aims to provide more effective therapeutic options by targeting multiple synergistic pathways simultaneously. The company is supported by prominent venture capital investors and maintains a robust pipeline of multi-specific antibody candidates.